Citations

Clear

3042 citation(s) found for "Kumar, S".

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Predicting Prognosis in Primary Sclerosing Cholangitis: Conventional to Functional MRI
Thompson, Cole P. , Aswani, Yashant , Carey, Elizabeth J. , Silva, Aubrienne N, Panda, Anshuman J, Venkatesh, Sudhakar K , Silva, Alvin C , Sandrasegaran, Kumar

Mayo Clinic

RadioGraphics | October 29, 2026 | Volume: 46 | Issue: 11 | Pages: No page available

10.1148/rg.260030 | PMID 42955837 Get It

MRI and MR cholangiopancreatography are central to the diagnosis, surveillance, and assessment of primary sclerosing cholangitis, while functional techniques such as MR elastography and gadoxetate-enhanced MRI provide complementary evolving biomarkers with potential prognostic value and utility for risk stratification.
Snare‐Assisted Retrieval of a Mechanically Locked‐Open TEER Device: A Novel Bailout Technique
Kaliyamoorthy, Dhamodaran , Murugesan, Kannan , Mahesh Kumar, Aishwarya

Mayo Clinic

Catheterization and Cardiovascular Interventions | October 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ccd.70957 | PMID 42949126 Get It

ABSTRACT Transcatheter edge‐to‐edge repair (TEER) is an established intervention for patients having severe mitral regurgitation (MR) with prohibitive surgical risk. Complications during deployment related to device malfunction are uncommon but necessitate prompt decision‐making and management. A 54‐year‐old gentleman with dilated cardiomyopathy, severe left ventricular dysfunction, and severe MR underwent TEER using the MyClip system (Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India). Initial deployment across the A2−P2 scallops of mitral leaflets achieved partial MR reduction. Significant residual MR required a second clip for optimal leaflet coaptation. While deploying the second clip, it failed to close because of a mechanical locking failure. So, we everted the clip, pulled back to LA, and it stayed in open position and failed to close. We report a novel bailout snare technique that enabled safe retrieval without the need for a second transseptal puncture. The ability to close the clip arms prior to withdrawal minimized the risk of tearing the atrial septum and facilitated the successful completion of the TEER procedure. Another clip was deployed successfully, resulting in significant MR reduction. This case demonstrates a rare complication during deployment, a malfunction of the device, and a novel strategy for safely bailing out a challenging intra‐procedural complication.
Metformin Preserves Regional Brain Glucose Uptake, Structure, and Functional Connectivity in Adults with Insulin Resistance
Ruegsegger, Gregory N. , Klaus, Katherine A. , Sevits, Kyle J., Leija, Robert G. , Prabha Kumar, Arathi, Sinhawansa, Sumaiya

Mayo Clinic

Journal of Clinical Investigation | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1172/jci207388 | PMID 42944764 Get It

BACKGROUND. Dementia is a rapidly expanding public health problem with major socio-economic burden. Insulin resistance (IR) is a prevalent but modifiable risk factor for dementia, yet its effects on brain structure, functional connectivity, and metabolism remain incompletely understood. METHODS. Regional brain glucose uptake (PET), volumes (MRI), functional connectivity (fMRI), and cognition (NIH Toolbox) was measured in 72 adults with or without markers of IR. To evaluate reversibility of IR-associated brain deficits, forty older adults with IR were randomized to forty weeks of metformin or placebo, and brain measures were repeated. As a proof-of-concept experiment, we developed a conditional brain-specific insulin receptor knockout mouse and assessed brain mitochondrial function and cognition. RESULTS. In older adults with markers of IR is associated with diminished total and regional brain volumes in areas critical for neuronal connectivity, memory, and learning, including cerebral white matter and the hippocampus. Reduced functional connectivity between brain regions detrimental for cognition was also noted. Further, we demonstrated that ATP production, essential for neuronal connectivity, was diminished in neuron-specific insulin receptor knockout mice accompanied by deficits in hippocampal- and prefrontal-dependent tasks. Forty weeks of metformin improved systemic insulin sensitivity concurrent to preserved brain glucose uptake, volume, and functional connectivity within specific regions central to decision-making and learning. Metformin was also associated with an improved composite measure of processing speed and working memory. CONCLUSION. These findings highlight IR as a key regulator of brain metabolism and support the concept that insulin sensitization can prevent neurobiological deficits in older people with IR.
Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (alliance)
Lee, Seohyuk , Ma, Chao , Shi, Qian , Kumar, Pankaj , Krishnamurthi, Smitha , Meyerhardt, Jeffrey A

Mayo Clinic

JNCI Cancer Spectrum | October 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jncics/pkag112 | PMID 42902778 Get It

Abstract Introduction We sought to evaluate the associations of post-diagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial. Methods We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months post-randomization. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (overall survival [OS]) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods. Results Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not significantly associated with survival outcomes, with a hazard ratio (HR) (95% confidence interval [CI]) of 1.01 (0.75-1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate significant associations with DFS or OS after Bonferroni correction. Conclusion Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes. ClinicalTrials.gov identifier: NCT01150045
Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
Greenall, Sam A , Chen, Shengnan C , Alton, Gordon , Beaton, Graham , Casey, Mattie , Babic, Ivan , Tucci, Fabio C , Ravula, Satheesh B , Stein, Gregory D , Li, Yuchen , D'Souza, Rochelle , Kumar, Ashwani , Kittler, Ralf , Tuma, Ann C M, Sarkaria, Jann N , Gough, Daniel J , Stewart, Rodney A , Kesari, Santosh , Day, Bryan W , Johns, Terrance G

Mayo Clinic

No container title available | October 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.14.759257 | PMID 42995774 Get It

Background: Glioblastoma (GBM) remains uniformly fatal. The basic helix-loop-helix transcription factor OLIG2 is universally expressed in diffuse glioma, sustains the tumor-propagating stem-like fraction, and opposes p53-mediated genotoxic responses, but has historically been considered undruggable. We characterized CT-179, a brain-penetrant small-molecule OLIG2 inhibitor, as a candidate therapeutic for GBM. Methods: Target engagement was assessed by cellular thermal shift assay, differential scanning fluorimetry, crosslinking, and electrophoretic mobility shift assay. Anti-tumor activity was evaluated across eleven patient-derived GBM cell lines, in zebrafish oligodendrocyte precursor cell (OPC)-derived tumors, and orthotopic and subcutaneous GBM models, including combinations with radiotherapy plus temozolomide and with selective Bcl-2 family inhibitors. Results: CT-179 engaged OLIG2 and altered the conformation of dimerized OLIG2 on chromatin without preventing dimerization or fully displacing OLIG2 from DNA. CT-179 reduced OLIG2-positive OPCs and OPC-derived tumors in zebrafish and inhibited proliferation across all eleven GBM lines (IC50 < 360 nM), depleting the stem-like fraction and inducing apoptosis through mitotic catastrophe, mitotic slippage, or a hybrid response. RNA-seq across three patient-derived glioma stem cell lines identified β-tubulin gene isoforms as the most strongly CT-179-down-regulated transcripts at the early time point and showed correlated β-tubulin and OLIG2 expression in TCGA glioblastoma specimens. Combination with the Mcl-1 inhibitor S63845 or the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 produced greater-than-additive cytotoxicity. Oral CT-179 crossed the blood-brain barrier and extended median survival as a single agent across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 was associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 orthotopic xenografts. Combination of CT-179 with radiotherapy and temozolomide eliminated all GBM8 and 7 of 8 GBM4 subcutaneous xenografts without weight loss and significantly extended survival when combined with radiotherapy in MGMT-unmethylated GBM6 orthotopic xenografts (CT-179 administered intraperitoneally). Conclusions: CT-179 is a brain-penetrant inhibitor of an established GBM driver with single-agent and combination activity across several orthotopic models, supporting clinical development for GBM and translational evaluation in other OLIG2-dependent CNS malignancies.
Complications and Hospital Resource Utilization Associated with ECMO in COVID-19 ARDS with Acute Kidney Injury: Insights from United States National Inpatient Sample, 2020–2022
Arumairaj, Antony , Dhorajiya, Poojaben , Dhanani, Dili , Venkataswamy Reddy, Jyothika , Kumar, Abhishek Kumar Mariswamy Arun , Tashrifwala, Fatema Ali Asgar , Patel, Digantkumar , Korpu, Divya , Mittal, Jayesh

Mayo Clinic

Healthcare | October 19, 2026 | Volume: 14 | Issue: 20 | Pages: 3490

10.3390/healthcare14203490 | PMID 42940536 Get It

Background: Acute kidney injury (AKI) is a common complication of COVID-19-associated acute respiratory distress syndrome (ARDS), yet the impact of extracorporeal membrane oxygenation (ECMO) on outcomes in this high-risk population remains unclear. Methods: We performed a retrospective, survey-weighted study using the National Inpatient Sample (NIS) database from 2020–2022 to compare outcomes among adults hospitalized with COVID-19-associated ARDS and AKI managed with invasive mechanical ventilation (IMV) alone versus IMV and ECMO. The primary outcome was in-hospital mortality, while secondary outcomes included renal replacement therapy (RRT), complications, hospital length of stay (LOS), and healthcare utilization. Results: Among 198,395 hospitalizations with COVID-19 ARDS complicated by AKI, 4730 received IMV and ECMO. ECMO use was not associated with statistically significantly lower adjusted in-hospital mortality (adjusted odds ratio [aOR] 0.96, 95% CI 0.81–1.12). However, ECMO was associated with greater odds of RRT, intracranial hemorrhage, disseminated intravascular coagulation, cardiogenic shock, vasopressor use, tracheostomy, acute liver failure, deep vein thrombosis, ischemic stroke and ICU-acquired weakness. ECMO was also associated with longer LOS and higher hospitalization charges. Conclusions: Among hospitalizations with COVID-19-associated ARDS and AKI, ECMO was not associated with statistically significantly lower adjusted in-hospital mortality but was associated with markedly higher complication burden, longer hospitalization, and substantially greater healthcare resource utilization.
Endoscopic Decompression for Lateral Recess Stenosis Due to Vertebral Compression Fracture
Yasin Yavuz, Ahmed , Zarra, Francisco , Kumar, Harendra , Bozkurt, Ismail , Senturk, Salim

Mayo Clinic

Clinical Spine Surgery | October 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/bsd.0000000000002180 | PMID 42886585 Get It

Study Design: Case presentation. Objective: The interlaminar endoscopic lateral recess decompression (IE-LRD) represents a novel surgical alternative to consider in carefully selected cases, particularly when patients do not respond to conservative treatment. Background: Lumbar spinal stenosis (LSS) constitutes one of the most prevalent spinal conditions in the elderly population around the world. A myriad of causes have been elucidated, and although infrequent, vertebral compression fractures (VCF) may also cause LSS. Conservative treatment might be the first option; however, patients often require surgery. Methods: A 76-year-old woman with a medical history of dementia consulted for radicular pain in her left leg during the past 6 months, without any favorable response to conservative treatment. Neurological examination revealed a positive straight leg raising test on the left. A spine MRI revealed a VCF in L5, linked with spondylolisthesis (grade I) at L5–S1. An IE-LRD was planned, as the patient did not consent to a classical open surgery. The incision was placed over the inferior medial edge of the left L4 lamina. Following sequential dilatators, the working channel was located on the inferomedial edge of the left L4 lamina. Lateral fluoroscopy (LF) guided the entire procedure. During the procedure, laminotomy was extended cranially and caudally to ensure sufficient vertebral decompression. Results: After surgery, the patient was mobilized in the first 6 hours and discharged in the next 24 hours. Her lower back pain score improved significantly to 2–3, while her leg VAS pain improved to 0–1. After a follow-up for 18 months, the patient did not manifest complications or recurrences, and no additional treatment was carried out. Conclusion: (1) IE-LRD might be a useful and safe surgical procedure for the surgical management of LSS caused by VCF. (2) Consider this surgical alternative for elderly patients without a previous response to conservative medical treatment.
The Congenital Heart Surgeons’ Society Center for Research and Quality 2025 Annual Report
Jacobs, Jeffery P , DeCampli, William M , Honjo, Osami , Alsoufi, Bahaaldin , Jegatheeswaran, Anusha , Louis, James D. St. , Lambert, Linda M , Manlhiot, Cedric , Kumar, S Ram , Kirklin, James K. , Austin, Erle H , Overman, David M , Dearani, Joseph A. , Romano, Jennifer C , Blackstone, Eugene H.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21501351261477040 | PMID 42876309 Get It

The Congenital Heart Surgeons’ Society (CHSS) is viewed by many as one of the most prestigious professional societies dedicated to pediatric and congenital cardiac surgery. The CHSS Center for Research and Quality (CRQ) Fall 2025 Work Weekend was held in Chicago on Saturday, October 25, 2025. The purpose of this article is to summarize the proceedings of the CHSS CRQ Fall 2025 Work Weekend and to provide a 2025 Annual Report of the CHSS CRQ. At the CHSS CRQ Fall 2025 Work Weekend, multiple topics were discussed related to ongoing CHSS research and quality initiatives. The CHSS CRQ is evolving to keep pace with the rapid evolution of medical informatics and the ever-evolving regulatory issues of clinical research. This 2025 Annual Report of the CHSS CRQ summarizes some of the ongoing initiatives at CHSS CRQ designed to assure that the CHSS CRQ continues to lead innovative and collaborative clinical research to improve pediatric and congenital cardiac care.
The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer
Cheung, Dillon C , Deshpande, Anagha J, Sandrasegaran, Kumar

Mayo Clinic

The American Surgeon™ | October 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261495994 | PMID 42852719 Get It

Background Sarcopenia is associated with worse outcomes in pancreatic cancer patients, but longitudinal body composition changes during neoadjuvant therapy remain poorly understood. Methods A retrospective review identified patients who underwent pancreatectomy, either upfront or after neoadjuvant therapy, for pancreatic adenocarcinoma between 2011 and 2021. Skeletal muscle area, index, and mean attenuation were calculated from CT images throughout the treatment course to assess sarcopenia. Multivariable generalized linear and logistic regression models were used to assess associations between sarcopenia, neoadjuvant therapy, and postoperative outcomes. Results A total of 72 patients were included: 32 who underwent neoadjuvant therapy and 40 who underwent upfront surgery. Forty-one (57%) patients had sarcopenia at diagnosis (65% upfront surgery vs 47% neoadjuvant, P = 0.154). Post-neoadjuvant therapy, 15.6% developed and 18.8% resolved sarcopenia. Median skeletal muscle mean attenuation increased by 2.4 HU after neoadjuvant therapy ( P = 0.02). Patients receiving neoadjuvant therapy were more likely to undergo nutrition consultation prior to surgery (61% vs 7%, P = 0.003). Neoadjuvant therapy was also associated with higher postoperative albumin levels (β = 0.244; 95% CI 0.041-0.446). Baseline sarcopenia diagnosed by skeletal muscle area was associated with increased postoperative complications (OR 13.696; 95% CI 2.537-73.921), while neoadjuvant therapy did not significantly impact complications (OR 0.384; 95% CI 0.12-1.226). Conclusions Patients who completed neoadjuvant therapy and underwent resection did not have increased rates of sarcopenia and were more likely to receive preoperative nutrition consultation and have higher postoperative albumin levels. The neoadjuvant period may represent an opportunity for sarcopenia assessment, nutritional optimization, and multimodal prehabilitation prior to pancreatectomy.